PASG 8-K: SEC filing

Passage BIO

Filed with the SEC on · accession 0001140361-26-044811

PASG filed a 8-K (current report) with the SEC on Nov 19, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Passage BIO filed an 8-K furnishing a press release from Remix Therapeutics announcing updated Phase 1 data from its ARIA Phase 1/2 trial of REM-422 in adenoid cystic carcinoma, presented at the 2026 ENA Symposium.

Key details

RegistrantPassage BIO, Inc.
Third party issuing press release furnished by registrantRemix Therapeutics, Inc.
Chief financial officerKathleen Borthwick

✦ Ask GOAX AI about this filing — what it means for PASG, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PASG?

Click here

Frequently asked questions

What did PASG file with the SEC on Nov 19, 2026?

PASG filed a 8-K (SEC filing). Passage BIO filed an 8-K furnishing a press release from Remix Therapeutics announcing updated Phase 1 data from its ARIA Phase 1/2 trial of REM-422 in adenoid cystic carcinoma, presented at the 2026 ENA Symposium.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other PASG SEC filings

Get alerts when PASG files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days